Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2010 | 09-2010 | 06-2010 | 03-2010 | 12-2009 | |
| Sales | 14,464,000 | 12,820,000 | 11,921,000 | 12,356,000 | 13,145,000 |
| Cost of Goods | 4,524,000 | 3,662,000 | 3,206,000 | 3,096,000 | 3,667,000 |
| Gross Profit | 9,940,000 | 9,158,000 | 8,715,000 | 9,260,000 | 9,478,000 |
| Operating Expenses | 7,473,000 | 6,571,000 | 5,754,000 | 5,749,000 | 6,841,000 |
| Operating Income | 2,467,000 | 2,587,000 | 2,961,000 | 3,511,000 | 2,637,000 |
| Interest Expense | 196,000 | 188,000 | 175,000 | 133,000 | 156,000 |
| Other Income | 149,000 | 395,000 | 172,000 | 152,000 | 211,000 |
| Pre-tax Income | 2,420,000 | 2,794,000 | 2,958,000 | 3,530,000 | 2,692,000 |
| Income Tax | 155,000 | 475,000 | 521,000 | 582,000 | 369,000 |
| Net Income Continuous | 2,265,000 | 2,319,000 | 2,437,000 | 2,948,000 | 2,323,000 |
| Minority Interests | 96,000 | 44,000 | 20,000 | 15,000 | 18,000 |
| Net Income | $2,169,000 | $2,275,000 | $2,417,000 | $2,933,000 | $2,305,000 |
| EPS Basic Total Ops | 0.94 | 0.99 | 1.06 | 1.29 | 1.00 |
| EPS Basic Continuous Ops | 0.99 | 1.01 | 1.07 | 1.29 | 1.02 |
| EPS Diluted Total Ops | 0.94 | 0.99 | 1.05 | 1.28 | 1.02 |
| EPS Diluted Continuous Ops | 0.98 | 1.01 | 1.06 | 1.29 | 1.03 |
| EBITDA(a) | $3,381,000 | $3,824,000 | $3,626,000 | $4,272,000 | $2,637,000 |